| SGK1, or serum and glucocorticoid‑regulated kinase 1, is an AGC family serine/threonine kinase that acts as a downstream effector of PI3K signaling and a stress‑responsive regulator of ion transport, metabolism, survival and immune modulation across multiple tissues. The protein comprises an N‑terminal regulatory region with a hydrophobic motif and phosphatidylinositol‑binding elements and a C‑terminal kinase domain that shares structural and functional similarities with AKT, but differs in substrate spectrum and regulatory inputs, positioning SGK1 as an AKT-independent arm of PI3K outputs. Activation follows a sequential phosphorylation cascade in which mTORC2 phosphorylates the hydrophobic motif at Ser422, creating a docking site for PDK1, which then phosphorylates the activation loop threonine within the kinase domain and opens the ATP-binding site, yielding a catalytically competent kinase that can respond dynamically to extracellular stimuli such as glucocorticoids, growth factors and osmotic stress. Once active, SGK1 phosphorylates a broad set of membrane and cytosolic substrates, including ion channels (such as ENaC and various K⁺ and Ca²⁺ channels), Na⁺/K⁺‑ATPase, amino acid transporters and Na⁺‑coupled glucose transporters, thereby promoting sodium reabsorption, nutrient uptake, glycolysis, angiogenesis, and cell survival under stress. SGK1 also phosphorylates and modulates components of the WNK/SPAK/OSR1 network, linking it to coordinated regulation of renal electrolyte handling and blood pressure; dysregulated SGK1 activity enhances ENaC‑dependent Na⁺ retention and contributes to hypertension and salt‑sensitive cardiovascular disease. At the signaling‑pathway level, SGK1 operates within the PI3K/mTOR axis alongside AKT but can substitute or complement AKT in some contexts, with validated SGK1‑specific targets including FOXO3a, GSK3β and NDRG1, and with evidence that SGK1 supports survival, migration and therapy resistance in tumors even when AKT is inhibited. In cancer, SGK1 is frequently upregulated or hyperactivated and promotes proliferation, epithelial–mesenchymal transition, invasion, and chemoresistance by sustaining mTORC1 activity, enhancing glucose and amino acid uptake, stabilizing HIF‑1α, and modulating NF‑κB and other transcriptional programs, making it a rising target in oncology, distinct from but complementary to AKT. SGK1 also acts as a regulator of immune and fibrotic responses: it influences T‑cell differentiation and Th17/Treg balance, modulates macrophage function, and contributes to chronic graft‑versus‑host disease and organ fibrosis by affecting inflammatory signaling and fibroblast activation. In neurologic contexts, SGK1 expression and activity are altered in depression, neurodegeneration and ischemic injury, with roles in neuronal survival, synaptic function and stress responses that further broaden its physiological relevance. |
